Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Panitumumab plus FOLFOX versus FOLFOX alone in previously untreated metastatic colorectal cancer
2006-000170-70Phase 3Completed
- Sponsor
- Amgen
- Start
- Apr 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of panitumumab in colorectal cancer (CRC) and metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Amgen. Primary endpoint: Progression-free survival. Started Apr 2006; status: completed.
02
Drugs
panitumumab
03
Conditions
colorectal cancer (CRC)metastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2006-000170-70.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000170-70.